Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (551-560 of 738) with videos related to

Pageof 74
Sort By:
Journal of the American Society of Hypertension : JASH|January 10, 2017
An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systemsRolf Wachter, Marcel Halbach, George L Bakris, et al.
Cardiorenal Medicine|January 20, 2012
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation ProgramAdam Whaley-Connell, Andrew S Bomback, Samy I McFarlane, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2022
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD studyLuis M Ruilope, Bertram Pitt, Stefan D Anker, et al.
European Journal of Heart Failure|March 3, 2022
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trialGerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, et al.
Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.
Journal of Cardiac Failure|October 14, 2014
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methylMelanie P Chin, Danielle Wrolstad, George L Bakris, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Diabetes, Obesity & Metabolism|March 20, 2024
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regressionFrederick Berro Rivera, Grace Nooriza O Lumbang, Danielle Rose Magno Gaid, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 6, 2010
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation ProgramAdam Whaley-Connell, Brian S Pavey, Peter A McCullough, et al.
Pageof 74

Showing results (551-560 of 738) with videos related to

Sort By:
Pageof 74
Journal of the American Society of Hypertension : JASH|January 10, 2017
An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systemsRolf Wachter, Marcel Halbach, George L Bakris, et al.
Cardiorenal Medicine|January 20, 2012
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation ProgramAdam Whaley-Connell, Andrew S Bomback, Samy I McFarlane, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2022
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD studyLuis M Ruilope, Bertram Pitt, Stefan D Anker, et al.
European Journal of Heart Failure|March 3, 2022
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trialGerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, et al.
Circulation. Heart Failure|December 4, 2013
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)Patrick Rossignol, Daniela Dobre, John J V McMurray, et al.
Journal of Cardiac Failure|October 14, 2014
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methylMelanie P Chin, Danielle Wrolstad, George L Bakris, et al.
Lancet (London, England)|November 10, 2022
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P Schlaich, Marc Bellet, Michael A Weber, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Diabetes, Obesity & Metabolism|March 20, 2024
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regressionFrederick Berro Rivera, Grace Nooriza O Lumbang, Danielle Rose Magno Gaid, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 6, 2010
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation ProgramAdam Whaley-Connell, Brian S Pavey, Peter A McCullough, et al.
Pageof 74